Loading company…
Theranexus, based in Lyon, France, develops therapies for rare neurological diseases, with a lead candidate targeting Batten disease.
Founded in 2014 in Lyon, France, Theranexus focuses on treatments for rare neurological disorders. Its lead clinical candidate targets Batten disease. On September 15, 2020, the company raised EUR 2.245 million in a PIPE from Auriga Partners, Financière Arbevel and other investors. The company reported revenue of EUR 0 and an EBITDA of EUR -6,243,904.9 for 2022.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in